Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyPeach State infusion site-of-care Coverage Update …
    Ask Trek AI about this page
    CurrentPeach State Health PlanPolicy GA.PMN.34

    Infusion Therapy Site of Care Optimization

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy GA.PMN.34 alerts

    Get alerted when Policy GA.PMN.34 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and approval requirements for outpatient intravenous or injectable specialty infusion therapy and guidance for redirecting site of care among hospital outpatient, ambulatory infusion centers, offices, pharmacies, and home settings for Peach State Health Plan members.

    Policy Summary
    PayerPeach State Health Plan
    PolicyInfusion Therapy Site of Care Optimization
    Policy CodePolicy GA.PMN.34
    Change TypeNo material changes
    Effective DateJul 25, 2025
    Last ReviewDec 1, 2025
    Next Review DateDec 1, 2025
    Key ActionSubmit clinical documentation (office notes, labs, or other information) demonstrating member meets initial approval criteria and plan for transition to home or ambulatory infusion when applicable.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 1 yearTypical approval duration
    Extensive listJ-/Q-code examples
    Overrides policy when conflictingState law precedence
    6-monthRestart disruption
    06/2025Policy created

    Coverage and Medical Necessity Criteria

    Initial Approval Criteria

    Covered when ALL of the following are met for inpatient outpatient or non-hospital outpatient infusion:

    Initial Approval Criteria A: Member requires intravenous (IV) or injectable therapy in an in-network outpatient hospital department or non-hospital outpatient office or facility (see Appendix B).

    Provider must submit documentation (office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

    AND: Absence of appropriate lower-acuity alternatives: There is (i) no available home infusion provider, (ii) a lower-cost site of care cannot provide the administration, and/or (iii) the specialty pharmacy cannot provide the drug for the member

    See subcriteria a–e for acceptable justifications to authorize higher-acuity site of care.

    Subcriteria (one or more must apply): a) FDA‑approved indication requires administration in an outpatient hospital, office, or clinic; b) administration is the initial dose of treatment or a restart after a ≥6‑month disruption for a short duration (e.g., ~4 weeks) with plan to transition to home infusion or ambulatory infusion suite (AIS); c) submitted documentation demonstrates that home‑based therapy or AIS is a health risk due to physical or behavioral impairment (examples include severe venous access issues, lack of caregiver, cardiopulmonary disorder, inability to tolerate IV fluid loads, cognitive concerns); d) submitted medical/infusion records document severe or life‑threatening adverse events non‑responsive to pre‑medications, analgesics, steroids, antihistamines, fluids, or infusion rate reductions (examples: seizures, anaphylaxis with no other therapy options, myocardial infarction, renal failure); e) other documented clinical reasons as appropriate.6-month disruption (applies to subcriterion b)

    Non‑qualifying examples include trypanophobia, pediatrics, preference/convenience, frequent laboratory monitoring, and continuation of services from a previous plan.

    Continued Approval

    For continued approval:

    Continued Approval: Provider must submit medical records or infusion records to reassess the member’s site of care and document the ongoing need for monitoring and advanced treatment capabilities beyond routine infusion requirements.

    Approval duration: up to one year or length of drug approval.

    Per-code site-of-care coverage notes

    Coverage and site-of-care guidance tied to specific J- and Q-codes with explicit exclusions or exemptions

    Code-specific coverage notes: Per-code entries designate whether the agent is excluded from the site‑of‑care policy or has specified exemptions. Examples from the code list: J9217 is listed as excluded; J9271 and J9299 note that concurrent chemotherapy is an exemption to the site‑of‑care policy (and may include '1st visit in AIS'); Q5107 (bevacizumab-awwb/Mvasi) is listed as excluded; several bevacizumab Q‑codes (e.g., Q5126, Q5129) note 'ophthalmic indications excluded'; certain pegfilgrastim Q‑codes include '1st visit in AIS' notes. These entries are code‑level rules and must be applied in addition to the general initial/continuation criteria.

    Refer to the appendix/code table for the full list of J‑ and Q‑codes and their per‑code site/exemption notes.

    Non-qualifying examples for justifying transfer of care from home to a higher-acuity outpatient/hospital setting include situations where the concern is trypanophobia (fear of needles), routine pediatrics care, patient preference or convenience, need for frequent laboratory monitoring, or merely continuation of services from a previous Plan. These items do not, by themselves, establish the medical necessity for a higher-intensity site of care.

    Certain products and billing codes are explicitly identified with policy-level exclusions or with excluded indications. Examples shown in the code tables include entries marked as excluded (for example, portions of the J9217 and Q5107 listings) and agents with specified excluded indications such as ophthalmic indications excluded for some bevacizumab Q-codes. Providers should consult the per-code entries in the drug list for code-specific exclusion or exemption language when submitting authorization requests.

    This clinical policy governs site-of-care determinations for Peach State Health Plan; however, applicable state legislation and regulatory requirements take precedence where there is a conflict. Providers must follow any state-specific mandates that supersede this policy in their jurisdiction.

    Requests for outpatient IV or injectable therapy that do not meet the policy's initial approval criteria should be arranged in a less intensive site of care. The policy specifically directs that such services be provided in an alternate, less intensive site of care rather than authorizing the requested outpatient hospital or similarly higher-acuity setting unless there is documentation meeting initial-approval conditions (for example: no home infusion provider available, FDA-required administration setting, initial dose/restart after a 6-month disruption, documented health risk for home, or severe adverse events).

    Codes and Coding Guidance

    Examples of Specialty Infusion J-codes listed in Appendix BHCPCS
    J0129Abatacept / Orencia
    J0172Aducanumab-Avwa / Aduhelm
    J0180agalsidase beta / Fabrazyme
    J0202alemtuzumab / Lemtrada
    J0218Olipudase Alfa / Xenopozyme
    J0221Avalglucosidase alfa-ngpt / Nexviazyme / Lumizyme
    J0222patisiran / Onpattro
    J0223givosiran / Givlaari
    J0224lumasiran / Oxlumo
    J0225vutrisiran / Amvuttra
    1–10 of 75
    1/8
    Listed J- and Q-codes and related entriesmixed
    J1576Listed in drug list (multiple mappings shown in document)
    J1602Listed in drug list
    J1626Listed in drug list
    J1628Listed in drug list
    J1740Listed in drug list
    J1743Listed in drug list
    J1744Listed in drug list
    J1745Listed in drug list
    J1786Listed in drug list
    J1823Listed in drug list
    1–10 of 106
    1/11
    Restart disruption interval
    Restart disruption interval6-month disruption — initial dose or restart after a 6-month treatment interruption may be authorized for a short duration (example: 4 weeks) with plan to transition to home infusion or ambulatory infusion suite.
    Required provider action for restartProvider must submit request for initial visit documenting plan for continued administration at home infusion or ambulatory infusion suite.
    Typical short-duration exampleExample short duration noted: 4 weeks when used for initial dose or restart prior to transition.
    Site-specific qualifiers
    Concurrent chemotherapy exemptionSeveral agents (e.g., pembrolizumab J9271; nivolumab J9299; multiple Q-codes) list 'concurrent chemotherapy is an exemption to policy.'

    Provider Responsibilities and Authorization Requirements

    Prior Authorization

    Prior authorization required with clinical documentation

    Prior authorization is required for outpatient hospital or non-hospital outpatient administration of IV or injectable therapy. Submit clinical documentation demonstrating the member meets the initial approval criteria (see Initial Approval Criteria) when requesting authorization for infusion in these settings.

    • Documentation examples: office chart notes, lab results, other clinical information showing criteria are met.
    Prior Authorization

    Code-level site-of-care notes, exclusions, and exemptions — check per code

    Many listed J- and Q-codes include site-of-care notes, with some codes explicitly excluded or having specific exemptions (e.g., maintenance, concurrent chemotherapy exemption, ophthalmic indications excluded, '1st visit in AIS'). Verify code-specific site guidance when requesting authorization.

    • Examples in the table: J9217 marked 'excluded'; J9271/J9299 note 'concurrent chemotherapy is an exemption'; Q5107 marked 'excluded'; several bevacizumab Q-codes note 'ophthalmic indications excluded'; certain pegfilgrastim Q-codes note '1st visit in AIS'.

    Background and Scope

    Specialty infusion therapy comprises intravenous or injectable administration of complex or chronic therapies that often require monitoring, specialized equipment, or trained personnel. Site-of-care optimization seeks to redirect administration and/or dispensing from higher-intensity outpatient facilities (such as hospital outpatient departments or community offices) to lower-cost, clinically appropriate settings (including home, ambulatory infusion centers/suites, or pharmacy) when safe and feasible. Authorization for higher-acuity sites is limited to circumstances that meet the policy's predefined criteria (for example, initial dose or restart after a 6-month disruption, absence of an available home infusion provider, FDA-required administration setting, significant physical or behavioral impairments that make home care unsafe, or severe, treatment-limiting adverse events).

    Definitions and Key Terms

    Site of Care — definition and examples
    Definition of Site of CareRedirection of administration and/or dispensing of specialty drugs from outpatient facilities (e.g., hospitals Place of Service 19 or 22, community office POS 11) to home-based settings (POS 12), ambulatory infusion centers/suites (POS 24 or 11), or pharmacy (POS 01).
    Examples of alternate settingsHome (POS 12), ambulatory infusion center or Ambulatory Infusion Suite (POS 24 or 11), and pharmacy (POS 01) are cited as lower-intensity alternate sites of care.
    When redirection appliesHigher-acuity outpatient hospital or non-hospital outpatient sites are authorized only when criteria are met (e.g., no home infusion provider, FDA-required outpatient administration, initial dose/restart, health risk for home, or severe adverse events); otherwise care should be provided in a less intensive site.
    Documentation and plan requirementProvider must submit documentation and, for initial/restart visits, a plan to transition to home infusion or AIS as applicable.
    Health Plan — definition

    Initial Therapy — Medical Necessity

    Initial Therapy

    Initial therapy conditions that may require outpatient/hospital administration

    Initial dose / Restart after disruption: Administration of the initial dose of treatment or restart of treatment after a ≥6‑month disruption for a short duration (example: ~4 weeks). Provider must submit request for the initial visit with a plan for continued administration at home infusion or ambulatory infusion suite (AIS).6-month disruption

    Plan/intent to transition to home infusion or AIS is required; this is a limited, short duration authorization.

    Severe or life‑threatening adverse events: Submitted medical or infusion records documenting severe or life‑threatening adverse events that were non‑responsive to pre‑medications, analgesics, steroids, antihistamines (e.g., diphenhydramine), fluids, or infusion rate reductions. Examples: seizures, anaphylaxis without other therapy options, myocardial infarction, renal failure.

    Such events may justify a higher‑acuity site of care.

    Continuation Therapy — Ongoing Approval Rules

    Continuation Therapy

    Rules for continued therapy approvals and reassessment of site of care

    Continuation Therapy: For ongoing therapy at the requested location, the provider must submit medical records or infusion records that justify continued need for the requested site by documenting the requirement for monitoring or advanced treatment capabilities beyond routine infusion care.

    Approval duration: up to one year or length of drug approval.

    Transition Plan and Step-Therapy Intent

    StepConditionRequired Provider ActionPlanned Transition / Duration
    1Initial administration or restart after ≥6-month disruptionSubmit request for initial visit and clinical documentation supporting need for outpatient hospital/office administrationShort duration (e.g., ~4 weeks) with documented plan to transition to home infusion or ambulatory infusion suite (AIS)

    Site-of-Care Settings and Determinations

    Note

    Site-of-care categories and example POS codes

    Site of care categories include home, office, ambulatory infusion center/AIS, and hospital outpatient; Place of Service codes are provided in the policy for context (examples: home = POS 12, office = POS 11, hospital outpatient = POS 19 or 22, AIS = POS 24 or 11).

    • Home — Place of Service Code 12
    • Office — Place of Service Code 11
    • Hospital outpatient — Place of Service Codes 19 or 22
    • Ambulatory infusion center / AIS — Place of Service Code 24 or 11
    Note

    Agent-specific site-of-care exclusions & exemptions

    Many agents have site-of-care notes; some agents or codes are excluded from this policy, while others carry exemptions such as concurrent chemotherapy, ophthalmic indications excluded, or '1st visit in AIS'.

    Note
    Policy Summary
    PayerPeach State Health Plan
    PolicyInfusion Therapy Site of Care Optimization
    Policy CodePolicy GA.PMN.34
    Change TypeNo material changes
    Effective DateJul 25, 2025
    Last ReviewDec 1, 2025
    Next Review DateDec 1, 2025
    Key ActionSubmit clinical documentation (office notes, labs, or other information) demonstrating member meets initial approval criteria and plan for transition to home or ambulatory infusion when applicable.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCodes and Coding GuidanceProvider Responsibilities and Authorization RequirementsBackground and ScopeDefinitions and Key TermsInitial Therapy — Medical NecessityContinuation Therapy — Ongoing Approval RulesTransition Plan and Step-Therapy IntentSite-of-Care Settings and Determinations
    Ophthalmic indications excluded
    Bevacizumab biosimilars and related codes (examples: Q5107 noted as excluded; Q5126, Q5129) are documented with 'ophthalmic indications excluded.'
    '1st visit in AIS' qualifierCertain pegfilgrastim/infliximab entries (e.g., Q5111, Q5118 group, Q5121/Q5122 notes) include '1st visit in AIS' as a site-specific qualifier.
    Maintenance notesSome codes (for example J9218) include a 'Maintenance' qualifier indicating a maintenance therapy context in code-level notes.
    Prior Authorization

    Coverage decisions may require prior authorization per Health Plan

    Coverage decisions and benefit administration are subject to the Health Plan's terms and may require prior authorization per the plan's administrative policies and procedures; follow plan documents when requesting coverage.

    • The clinical policy is a guide to medical necessity but does not guarantee payment; check evidence of coverage, contracts, and applicable state/federal requirements.
    Step Therapy

    Short-duration approval for initial dose or restart with transition plan

    Initial administration or restart after a ≥6-month disruption may be authorized for a short duration (example: ~4 weeks) only if the provider requests the initial visit and documents a plan to transition continued administration to home infusion or an ambulatory infusion suite (AIS).

    • Provider must submit the request for the initial visit including the plan for continued home or AIS administration.
    Step Therapy

    Follow per-agent site-of-care flow notes (maintenance, exemptions, AIS first visit)

    Certain agents include site-related flow notes (e.g., 'maintenance', 'concurrent chemotherapy is an exemption', '1st visit in AIS') that indicate permitted site-of-care pathways rather than classical step edits; apply these per-agent conditions when planning site of administration.

    • Use the per-code table to determine if maintenance therapy, concurrent chemotherapy exemptions, or '1st visit in AIS' apply for the requested agent.
    Note

    Include code-specific site justification and duration in request

    Per the document's per-code entries and tables, providers should follow code-specific site guidance and include any required site justification and duration (for example, initial-visit short-duration approvals) when submitting requests.

    • Include code(s) being requested and reference the per-code note (e.g., maintenance, exemption for concurrent chemotherapy, ophthalmic exclusion, '1st visit in AIS').
    Documentation Required

    Submit supporting clinical documentation with authorization request

    Providers must submit documentation (office chart notes, lab results, infusion records, or other clinical information) supporting that the member meets all approval criteria when requesting authorization.

    • Include clinical evidence supporting any claimed reasons for higher-acuity site (no home infusion provider, contraindication to home/AIS, severe prior adverse events, etc.).
    Documentation Required

    Document dosing per FDA label or manufacturer's package insert

    Dosing and administration must follow the FDA approval or the manufacturer's package insert; reference the FDA label or package insert for specific dosing when documenting the request.

    • Use the manufacturer's prescribing information as the authoritative source for dose and administration details included in the request.
    Documentation Required

    Provide documentation consistent with clinical policy and plan coverage rules

    Follow this clinical policy as a guide to medical necessity and submit documentation supporting medical necessity per the Health Plan's coverage documents and applicable laws when requesting authorization.

    • Ensure submitted documentation aligns with plan terms, exclusions, and state/federal requirements referenced by the Health Plan.
    Denial Risk

    Risk of denial for site-of-care mismatch — provide in less intensive setting if criteria not met

    Requests for outpatient IV or injectable therapy that do not meet the Initial Approval Criteria should be provided in a less intensive alternate site of care; authorization for the requested higher-acuity site may be denied.

    • Non-qualifying examples (e.g., preference/convenience, trypanophobia, pediatrics, frequent lab monitoring, continuation from prior plan) do not justify higher-acuity site.
    Billing Rule

    Verify code-level exclusions and exemptions before requesting authorization

    Certain J- and Q-codes are explicitly excluded or have specified exemptions noted in the per-code table; verify code-level exclusions or exemptions before submitting a request to avoid inappropriate authorization attempts.

    • Examples: J9217 is marked 'excluded'; Q5107 marked 'excluded'; several bevacizumab and other Q-codes note 'ophthalmic indications excluded' or other exclusions.
    Denial Risk

    Denial risk if request does not meet policy, benefit terms, exclusions, or legal requirements

    Requests or claims may be denied if they do not meet the clinical policy, the Health Plan's benefit terms, or applicable exclusions, limitations, and regulatory requirements; ensure all elements of medical necessity and coverage are documented.

    • Denials can result from failure to meet criteria, benefit exclusions, code-level exclusions, or conflicts with state/federal law or plan administrative policies.
    Health Plan definition'Health Plan' means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.
    Policy applicabilityThis clinical policy is a guide to medical necessity to assist in coverage decisions and administering benefits; it does not constitute a contract or guarantee of payment.
    Compliance with law and plan termsCoverage decisions are subject to all terms, exclusions, limitations of coverage documents and applicable state and federal requirements; state law/regulation governs if discrepant with policy.
    Health risk for home or AIS:
    Submitted documentation that home‑based therapy or ambulatory surgical/infusion center presents a health risk due to physical or behavioral impairment (examples: severe venous access issues where vein finder unavailable, no caregiver access, cardiopulmonary disorder, inability to tolerate IV fluid loads, cognitive concerns impacting patient safety).

    These are illustrative examples, not exhaustive.

    Home/site determinations must follow state law

    Site-of-care determinations in this policy must comply with applicable state legislation and regulatory requirements, which take precedence when they conflict with the policy.